home / stock / immp / immp news

IMMP News and Press, Immutep Limited From 09/14/22

Stock Information
Company Name: Immutep Limited
Stock Symbol: IMMP
Market: NASDAQ
Website: immutep.com
Menu
IMMP IMMP Quote IMMP Short IMMP News IMMP Articles IMMP Message Board
Get IMMP Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMP - Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) Planning and regulatory interactions ongoing with a focus now prioritising 1 st ...
IMMP - Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased ...

IMMP - Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Expansion of the efti clinical development pipeline with a new Phase II setting Efti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by the Polish government Collaboration with the Maria Skłodowska-Curie ...

IMMP - Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep ( NASDAQ: IMMP ) said the Japanese Patent Office granted a new patent for eftilagimod alpha in combination with a PD-1 pathway inhibitor. The patent titled, 'Combined Preparations for the Treatment of Cancer or Infection' protects intellectual pr...
IMMP - Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...

IMMP - Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Encouraging efficacy results continue for patients with 2 nd line PD-X refractory non-small cell lung cancer (NSCLC) Patients in this 2 nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (“PD-X”) based 1 st line therapy 1 Key ...

IMMP - Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep ( NASDAQ: IMMP ) said it received a patent from the Japanese Patent Office related to its pre-clinical product candidate IMP761. The patent number number 7074341 titled 'Anti-LAG-3 Antibodies' is related to pharmaceutical compositions comprising ...
IMMP - Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of ...

IMMP - Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from...

IMMP - Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. However, IMMP has a long way to go. For further details see: Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Previous 10 Next 10